Teplizumab in Pediatric Stage 2 Type 1 Diabetes
Completed · Phase 4 · NCT05757713
Conditions: Diabetes Mellitus, Type 1
At a glance
- Research payments reported, 2025
- $193,880
- U.S. investigators named
- 3
- Sites paid
- 5
- Planned or actual enrollment
- 23
About the trial
- Sponsor
- Sanofi
- Tested
- teplizumab (biological)
- Dates
- Started 2023-07-25; completion 2026-08-28
- Results posted
- Not yet
The purpose of this study is to assess the safety and pharmacokinetics (PK) of teplizumab in participants with Stage 2 type 1 diabetes who are \<8 years of age.
From ClinicalTrials.gov, last updated 2026-09-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $193,880 in research payments for this study in 2025 (40 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Stephen E. Gitelman, M.D. Pediatric Endocrinology · San Francisco, CA
- Peter Gottlieb, MD Endocrinology & Diabetes · Aurora, CO
- Steven M. Willi, M.D. Pediatric Endocrinology · Philadelphia, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Tacoma General Allenmore Hospital, WA $152,150
- $15,750
- Uci Health-Orange, CA $13,044
- Regents of the University of Colorado $8,574
- Childrens Hospital of Philadelphia Radiology $2,211
- The Childrens Hospital of Philadelphia Research Institute $2,151
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.